Putting the document online
“Q
1 2022
Memorandum
for
modeling
purposes
»
Paris, March 30, 2022
. Sanofi announces the posting on the Investors section of the company’s website of a document entitled “Q1 2022 Memorandum for modeling purposes”.
https://www.sanofi.com/en/investors/results-and-events/financial-results/results-Q1-2022
Like every quarter, this document aims to assist the financial community in modeling the Company’s quarterly results. This document contains a reminder of various non-recurring items and losses of exclusivity, the effect of currency variations and the number of shares. The results for the first quarter of 2022 will be announced on April 28, 2022.
AT
in relation to
Sanofi
We are an innovative, global health company driven by one purpose: to pursue the miracles of science to improve people’s lives. Our teams, present in a hundred countries, are working to transform the practice of medicine to make the impossible possible. We provide therapeutic solutions that can change the lives of patients and vaccines that protect millions of people around the world, guided by the ambition of sustainable development and our social responsibility.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media relations
Sandrine Guendoul
| + 33 6 25 09 14 25 |
Sally Bath
| + 1 617 834 6026 |
Victor Rouault
| + 33 6 70 93 71 40 |
Investor Relations
Eva Schaefer-Jansen
| + 33 7 86 80 56 39 | [email protected]
Arnaud
Delepine
| + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt
| + 33 6 40 56 92 21 | [email protected]
Felix Lauscher
| + 1 908 612 7239 | [email protected]
Priya Nanduri
| +1 908 981 5560 | [email protected]
Nathalie Pham
| + 33 7 85 93 30 17 | [email protected]
Forward-looking statements
This press release contains forward-looking statements. These statements do not constitute historical facts. These statements include projections and estimates and the assumptions on which they are based, statements relating to plans, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance. These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan”, and other similar terms. Although Sanofi’s management believes these forward-looking statements to be reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties, which are difficult to predict and generally beyond Sanofi’s control, which may mean that actual results and events realized differ materially from those expressed, implied or anticipated in the forward-looking information and statements. These risks and uncertainties include, but are not limited to, uncertainties inherent in research and development, future clinical data and analyses, including post-marketing, decisions by regulatory authorities, such as the FDA or EMA, approval whether or not, and on what date, of the drug, process or biologic application for any of these product candidates, as well as their decisions regarding labeling and other factors that may affect the availability or commercial potential of such product candidates, the fact that the product candidates if approved may not achieve commercial success, the future approval and commercial success of alternative therapeutics, the ability to Sanofi to seize external growth opportunities and finalize related transactions, changes in exchange rates and interest rates, unstable economic and market conditions é, cost containment initiatives and their evolution, the impact that COVID-19 will have on Sanofi, its customers, suppliers and partners and their financial situation, as well as on its employees and on the global economy. Any significant impact on these could negatively impact Sanofi. The situation is changing rapidly and other consequences of which we are unaware could appear and exacerbate the risks previously identified. These risks and uncertainties also include those discussed or identified in Sanofi’s public filings with the AMF and the SEC, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of the Registration Document. universal registration 2021 of Sanofi, which has been filed with the AMF as well as in the sections “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” of the 2021 annual report on Form 20-F of Sanofi, which has been filed with the SEC. Sanofi makes no commitment to update forward-looking information and statements subject to applicable regulations, in particular articles 223-1 et seq. of the general regulations of the Autorité des marchés financiers.
Attachment